Yan Leyfman Highlights Breakthrough Study on Bispecific Antibodies in CNS Myeloma
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Mansi R Shah et al. published on British Journal of Haematology:
“Pioneering work from Dr. Mansi R Shah (Rutgers Cancer Institute) and colleagues!
CNS multiple myeloma (CNS-MM) remains a rare but aggressive manifestation with limited evidence-based treatment strategies. Historically, outcomes have been dismal, but novel immunotherapies may be shifting the paradigm.
In the first retrospective multicenter study of bispecific antibodies (BsAbs) for CNS-MM (9 patients across 3 US centers):
100% CNS response rate among evaluable patients
Responses seen with both BCMA- and GPRC5D-directed BsAbs
Importantly, some patients responded before adjunctive CNS therapy, suggesting intrinsic CNS activity
Safety profile was favorable: only grade 1–2 CRS, no ICANS
Why this matters:
- BsAbs offer off-the-shelf accessibility vs CAR-T (weeks of manufacturing)
- Potential for rapid CNS disease control in heavily pretreated patients
- May represent a new therapeutic option in an area of huge unmet need
- This pioneering work highlights the potential of BsAbs to penetrate the CNS and improve outcomes for patients with CNS-MM — but
- larger prospective studies are urgently needed.”
Title: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort
Authors: Alexandra Noveihed, Samer Al Hadidi, Meera Mohan, Mansi R. Shah
Read the full article.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023